The
nice people at “The Oncologist” sent
their update today. As usual with their stuff it was far more “background information” for me than it
as anything directly applicable to my daily round. But valuable reading
nonetheless.
Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)‐ERIBE
Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust
No comments:
Post a Comment